Buy Evista (Raloxifene 60mg) Online - Original Eli Lilly Brand Cipla Generic SERM Osteoporosis Prevention
Evista (Raloxifene 60 mg) represents the second-generation Selective Estrogen Receptor Modulator (SERM) - the fundamental postmenopausal medication providing tissue-selective estrogen receptor activity with dual FDA-approved indications for postmenopausal osteoporosis prevention and treatment, plus invasive breast cancer risk reduction in high-risk postmenopausal women. Originally developed by Eli Lilly and Company and FDA-approved as Evista in 1997 for postmenopausal osteoporosis with additional approval in 2007 for invasive breast cancer risk reduction, raloxifene has over 25 years of continuous clinical use as the reference tissue-selective estrogen modulator. Evista on rxshop.md is manufactured by Cipla Limited - one of India's largest pharmaceutical companies with WHO-GMP certification and US FDA-inspected manufacturing facilities serving global markets.
Raloxifene works as a tissue-selective estrogen receptor modulator providing a unique combination of estrogen-agonist and estrogen-antagonist activity depending on target tissue. First, raloxifene acts as estrogen agonist at bone tissue - suppressing osteoclast activity, preserving bone density, and reducing vertebral fracture risk. Second, raloxifene acts as estrogen agonist at lipid metabolism - reducing LDL cholesterol with neutral HDL effects. Third, raloxifene acts as estrogen antagonist at breast tissue - blocking estrogen-driven breast cancer development. Fourth, raloxifene acts as estrogen antagonist at endometrium - providing no endometrial stimulation (major safety advantage over tamoxifen which increases endometrial cancer risk).
Evista addresses two major postmenopausal health concerns simultaneously. Clinical trials demonstrate 50-60 percent vertebral fracture risk reduction in postmenopausal osteoporosis and 76 percent invasive breast cancer risk reduction in high-risk postmenopausal women (STAR trial data). Unlike hormone replacement therapy, Evista provides osteoporosis protection without vasomotor symptom relief and without stimulating breast or endometrial tissue. The 60 mg once-daily oral dosing provides convenient single-tablet therapy.
Please note: Evista is currently out of stock on rxshop.md. For alternative women's health medications during Evista unavailability, please browse our Women's Health category where you can find related hormone therapy options including Duphaston (dydrogesterone) for progestogen therapy in postmenopausal women, and consult with your healthcare provider about appropriate osteoporosis prevention alternatives.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Postmenopausal Osteoporosis Treatment: Active treatment of established postmenopausal osteoporosis reducing vertebral fracture risk substantially;
- Invasive Breast Cancer Risk Reduction: Reduction of invasive breast cancer risk in high-risk postmenopausal women per STAR trial evidence;
- Vertebral Fracture Prevention: Substantial reduction in spinal compression fracture risk from preserved vertebral bone density;
- Osteopenia: Bone density lower than normal but not yet osteoporotic requiring intervention to prevent progression;
- High Risk Breast Cancer: Postmenopausal women with elevated invasive breast cancer risk from family history or Gail Model assessment;
- Postmenopausal Bone Loss: Progressive bone density decline occurring after menopause requiring intervention to preserve skeletal integrity;
- Bone Density Loss: Progressive reduction in bone mineral density affecting skeletal strength and fracture susceptibility;
- Hormone Receptor Positive Cancer Prevention: Blocks estrogen-driven breast cancer development in high-risk postmenopausal women;
- Postmenopausal Women Therapy: Targeted therapy specifically for women after menopause not indicated for premenopausal use;
- SERM Class Therapy: Second-generation selective estrogen receptor modulator with tissue-specific agonist and antagonist effects;
- Osteoporosis Fracture Risk: Elevated fracture risk from low bone density affecting quality of life and mortality;
- Vertebral Compression Fracture Risk: Risk of painful spinal compression fractures from weakened vertebral bone in postmenopausal women;
- Estrogen Deficiency Bone Loss: Accelerated bone resorption from postmenopausal estrogen deficiency requiring pharmacological intervention;
- HRT Alternative for Osteoporosis: Bone protection without vasomotor symptom relief or breast endometrial stimulation like traditional HRT;
- Bone Mineral Density Loss: Measurable decline in bone density on DEXA scan requiring intervention to prevent fractures;
- Family History Breast Cancer Risk: Elevated invasive breast cancer risk from documented family history requiring preventive intervention;
- Breast Cancer Chemoprevention: Use of medication to prevent invasive breast cancer development in high-risk individuals;
- Tissue Selective Estrogen Modulation: Different effects on bone breast endometrium and lipids providing selective therapeutic benefits;
- Non-Hormonal Osteoporosis Alternative: Bone protection alternative for women unable or unwilling to use estrogen hormone replacement therapy.
- Prevents Invasive Breast Cancer: 76 percent invasive breast cancer risk reduction in high-risk postmenopausal women per STAR trial evidence;
- Preserves Bone Density: Increased spine and hip bone mineral density on DEXA scan over years of continuous therapy;
- No Endometrial Stimulation: Zero endometrial cancer risk unlike tamoxifen - major safety advantage of raloxifene therapy;
- No Breast Tissue Stimulation: Estrogen-antagonist activity at breast provides breast cancer risk reduction without stimulation;
- Reduces LDL Cholesterol: Modest reduction in LDL cholesterol with neutral HDL effects providing cardiovascular lipid benefits;
- Selective Menopausal Symptom Profile: Does not stimulate breast or endometrium and does not typically worsen vasomotor symptoms;
- Once Daily Convenience: Simple 60 mg tablet once daily provides convenient long-term therapy regimen;
- Oral Tablet Administration: Simple oral therapy avoiding injections infusions or complex administration procedures;
- Tissue Selective Action: Different effects on bone breast endometrium lipids providing targeted therapeutic benefits;
- No Withdrawal Bleeding: Unlike combined HRT does not cause monthly withdrawal bleeding in postmenopausal women;
- Dual Indication Benefit: Simultaneous osteoporosis protection and invasive breast cancer risk reduction from single medication;
- Better Safety vs Tamoxifen: Fewer thromboembolic events than tamoxifen in STAR trial with equivalent breast cancer prevention;
- Long Term Therapy Option: Suitable for years of continuous therapy with established safety profile monitoring;
- Eli Lilly Original Brand Heritage: FDA-approved 1997 with over 25 years continuous clinical use worldwide;
- Cipla Manufacturing Quality: WHO-GMP and US FDA-inspected manufacturing standards providing bioequivalent generic quality;
- Non-Hormonal Alternative: SERM class alternative for women unable to use traditional estrogen hormone replacement therapy;
- Reduces Hip Fracture Risk: Contributes to overall fracture risk reduction in postmenopausal osteoporosis therapy;
- Cardiovascular Neutral Lipids: Neutral to modestly favorable lipid profile effects during long-term therapy;
- Better Quality of Life: Combined osteoporosis protection and breast cancer risk reduction dramatically improves postmenopausal quality of life and health outcomes.
Generic Evista (Raloxifene 60 mg) Medication guide:
Evista (Raloxifene 60 mg) represents the second-generation Selective Estrogen Receptor Modulator (SERM) - the fundamental postmenopausal medication providing tissue-selective estrogen receptor activity with dual FDA-approved indications for postmenopausal osteoporosis prevention and treatment, plus invasive breast cancer risk reduction in high-risk postmenopausal women. Originally developed by Eli Lilly and Company and FDA-approved as Evista in 1997 for postmenopausal osteoporosis with additional 2007 approval for invasive breast cancer risk reduction, raloxifene has over 25 years of continuous clinical use as the reference tissue-selective estrogen modulator. Evista on rxshop.md is manufactured by Cipla Limited - one of India largest pharmaceutical companies with WHO-GMP certification and US FDA-inspected manufacturing facilities. Approved for postmenopausal osteoporosis prevention and treatment, and invasive breast cancer risk reduction in high-risk postmenopausal women per STAR trial evidence. This comprehensive medication guide covers every aspect of Evista therapy including SERM class pharmacology, tissue-selective mechanism of action, MORE trial osteoporosis data, STAR trial breast cancer prevention data, comprehensive dosing protocols, CRITICAL venous thromboembolism warnings, contraindications, drug interactions, and long-term therapy considerations.
💊 Introduction to Evista
Evista is a prescription oral medication containing raloxifene hydrochloride 60 mg as its active ingredient in tablet form. Raloxifene is a second-generation Selective Estrogen Receptor Modulator (SERM) - a class of medications that bind estrogen receptors and produce tissue-selective effects that mimic or block estrogen action depending on the target tissue. Raloxifene was originally developed by Eli Lilly and Company and received FDA approval as Evista in 1997 for postmenopausal osteoporosis prevention. Additional FDA approval was granted in 2007 for invasive breast cancer risk reduction in high-risk postmenopausal women based on the STAR trial results.
The Evista brand available on rxshop.md is manufactured by Cipla Limited - one of India largest pharmaceutical companies founded in 1935 with global operations in over 80 countries. Cipla maintains WHO-GMP certification, US FDA-inspected manufacturing facilities, EU-GMP certification, and multiple international regulatory approvals ensuring bioequivalent generic Evista of consistent pharmaceutical quality.
Evista occupies a distinctive position in postmenopausal health management as one of the few medications providing dual therapeutic benefits - simultaneous postmenopausal osteoporosis protection and invasive breast cancer risk reduction. Clinical trials demonstrate 50-60 percent vertebral fracture risk reduction in postmenopausal osteoporosis (MORE trial) and 76 percent invasive breast cancer risk reduction in high-risk postmenopausal women (STAR trial). This dual indication makes Evista uniquely valuable for postmenopausal women at elevated risk for both osteoporosis and invasive breast cancer.
Unlike traditional hormone replacement therapy (HRT), Evista provides these benefits without stimulating breast or endometrial tissue and without causing vasomotor symptom relief. This selectivity profile makes raloxifene particularly appropriate for postmenopausal women who cannot use estrogen HRT due to breast cancer risk, endometrial concerns, or personal preference. The 60 mg once-daily oral dosing provides simple long-term therapy for years of continuous protection.
🏭 Cipla Manufacturer Heritage
Cipla Limited Credentials
Cipla Limited credentials:
- Founded 1935 in Mumbai India - over 85 years pharmaceutical heritage
- Global operations in over 80 countries worldwide
- WHO-GMP certification - highest quality manufacturing standards
- US FDA-inspected facilities serving American regulatory market
- EU-GMP certification serving European market
- MHRA UK approval for United Kingdom distribution
- 50+ manufacturing facilities across multiple countries
- Third largest pharmaceutical company in India by revenue
- Extensive womens health portfolio including hormone therapy and reproductive medicine
- Established osteoporosis and cardiovascular product lines
Manufacturing Quality Standards
Cipla produces Evista generic raloxifene with rigorous quality control ensuring bioequivalent 60 mg raloxifene hydrochloride content per tablet, pharmaceutical-grade excipients, batch-to-batch consistency, stability testing for shelf-life reliability, and compliance with international pharmacopeia standards. The Cipla manufacturing infrastructure provides consistent quality supporting equivalent clinical effects to original brand Evista formulation.
📜 Evista Brand Heritage
Original Development Timeline
| Year | Development Milestone |
|---|---|
| 1970s-1980s | Eli Lilly research on benzothiophene derivatives - early SERM development |
| 1980s | Tamoxifen (first-generation SERM) established for breast cancer treatment |
| 1990s | Raloxifene developed as second-generation SERM addressing tamoxifen limitations |
| 1997 | FDA approval of Evista by Eli Lilly for postmenopausal osteoporosis prevention |
| 1999 | MORE trial (Multiple Outcomes of Raloxifene Evaluation) validates osteoporosis efficacy |
| 2006 | STAR trial results published - raloxifene equivalent to tamoxifen for breast cancer prevention |
| 2007 | Additional FDA approval for invasive breast cancer risk reduction in high-risk postmenopausal women |
| 2013 | Generic raloxifene became available following Evista patent expiration |
| Present Day | Over 25 years continuous clinical use worldwide - reference SERM for postmenopausal osteoporosis and breast cancer prevention |
Evista Significance in Postmenopausal Medicine
Evista introduction in 1997 represented a significant advance in postmenopausal medicine by providing the first SERM specifically developed for postmenopausal osteoporosis with favorable safety profile relative to first-generation SERM tamoxifen. The additional 2007 approval for invasive breast cancer risk reduction established Evista as the first medication with FDA-approved dual indications for both osteoporosis prevention and breast cancer risk reduction. The 2006 STAR trial demonstrating equivalent breast cancer prevention efficacy to tamoxifen with fewer venous thromboembolic events transformed clinical practice for high-risk postmenopausal breast cancer prevention.
🧬 Understanding SERMs Class
SERM Generations and Categories
SERM class categories:
- First-generation SERMs: Tamoxifen, toremifene (triphenylethylene derivatives) - primarily oncology use
- Second-generation SERMs: Raloxifene (benzothiophene derivative) - osteoporosis and prevention
- Third-generation SERMs: Bazedoxifene, ospemifene, lasofoxifene - refined selectivity
- Fertility SERMs: Clomiphene (mixed antagonist-agonist for ovulation induction)
- Vaginal SERM: Ospemifene - dyspareunia and vulvovaginal atrophy
Raloxifene Position Within SERM Class
Raloxifene occupies a distinctive position within the SERM class as the second-generation SERM specifically developed for postmenopausal osteoporosis with favorable safety compared to tamoxifen. Advantages include no endometrial stimulation (unlike tamoxifen which increases endometrial cancer risk), lower venous thromboembolism rate than tamoxifen, equivalent breast cancer prevention efficacy per STAR trial, dual FDA indication for osteoporosis and breast cancer prevention, benzothiophene chemistry providing enhanced tissue selectivity, and 25+ years of clinical experience supporting evidence-based prescribing.
🧪 Chemistry of Raloxifene
Chemical Structure
Raloxifene hydrochloride has the chemical formula C28H27NO4S·HCl with molecular weight approximately 510.05 g/mol. Chemically, raloxifene is a benzothiophene derivative - structurally distinct from first-generation SERM tamoxifen (triphenylethylene derivative). The benzothiophene backbone provides the structural foundation for tissue-selective estrogen receptor binding with unique conformational effects on receptor structure.
Structural Features
Raloxifene structural features:
- Benzothiophene core structure - distinctive from triphenylethylene tamoxifen
- Two hydroxyl groups at strategic positions mimicking estradiol
- Basic side chain containing piperidine ring - critical for antagonist activity
- Extensive first-pass metabolism with glucuronide conjugation
- Active glucuronide metabolites retain some biological activity
- Enterohepatic circulation contributes to prolonged effect
- High protein binding to albumin and alpha-1-acid glycoprotein
🔬 Tissue-Selective Mechanism of Action
Core Mechanism
Raloxifene mechanism at cellular level:
- Estrogen receptor binding: Raloxifene binds estrogen receptors alpha and beta with high affinity
- Tissue-specific conformational change: Receptor-ligand complex adopts different conformations in different tissues
- Coactivator recruitment: Recruits different transcriptional coactivators depending on tissue context
- Bone tissue - agonist activity: Recruits coactivators mimicking estrogen effect - suppresses osteoclast activity
- Breast tissue - antagonist activity: Recruits corepressors blocking estrogen-driven proliferation
- Endometrial tissue - neutral/antagonist: No significant endometrial stimulation - major safety advantage
- Lipid metabolism - agonist: Reduces LDL cholesterol with neutral HDL effects
- Vasomotor centers - antagonist: Does not relieve hot flashes and may worsen them
Tissue-Specific Effects Summary
| Tissue | Raloxifene Effect | Clinical Consequence |
|---|---|---|
| Bone | Agonist | Prevents osteoporosis - reduces vertebral fractures |
| Breast | Antagonist | Reduces invasive breast cancer risk |
| Endometrium | Neutral/Antagonist | No endometrial cancer risk - safety advantage vs tamoxifen |
| LDL Cholesterol | Agonist (reduces) | Modest LDL reduction - lipid benefit |
| HDL Cholesterol | Neutral | No significant HDL change |
| Vasomotor Centers | Antagonist | Does not relieve hot flashes - may worsen |
| Coagulation | Agonist (procoagulant) | Increased VTE risk (major warning) |
| Vaginal Tissue | Neutral/Antagonist | Does not relieve vulvovaginal atrophy |
🔬 Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral absorption | Approximately 60 percent | Good absorption but extensive first-pass metabolism |
| Oral bioavailability | Approximately 2 percent (parent) | Extensive first-pass glucuronidation - active metabolites remain |
| Time to peak (Tmax) | 4-6 hours | Delayed absorption due to extensive metabolism |
| Half-life | 27-32 hours | Long half-life supports once daily dosing |
| Protein binding | Approximately 95 percent | Binds albumin and alpha-1-acid glycoprotein |
| Metabolism | Hepatic glucuronidation | Extensive first-pass conjugation - no CYP450 involvement |
| Active metabolites | Glucuronide conjugates | Retain some biological activity |
| Enterohepatic circulation | Significant | Extends duration of therapeutic effect |
| Elimination | Fecal (primarily) | Approximately 90 percent fecal via bile |
| Steady state | Within 5 days | Rapid therapeutic effect assessment |
| Bone density changes | Months to years | Progressive bone density improvement over years |
🦴 Understanding Postmenopausal Osteoporosis
Postmenopausal Bone Loss
Postmenopausal osteoporosis overview:
- Accelerated bone loss begins with menopausal estrogen deficiency
- Rate of loss: 1-2 percent annually in early postmenopause
- Cumulative loss: 30-40 percent of trabecular bone in 20 years
- Fracture consequences: Vertebral hip and wrist fractures - major health impact
- Vertebral fractures: Cause height loss chronic pain and kyphosis
- Hip fractures: 20-25 percent mortality within first year
- DEXA scan diagnosis: T-score at or below negative 2.5 defines osteoporosis
- Osteopenia: T-score between negative 1.0 and negative 2.5 indicates low bone density
Raloxifene Mechanism in Osteoporosis
Raloxifene acts as estrogen agonist at bone tissue - binding estrogen receptors on osteoclasts and osteoblasts. This suppresses osteoclast activity (reducing bone resorption) while allowing continued osteoblast bone formation. The net effect is preservation of bone density and gradual increase in bone mineral density over years of continuous therapy. The MORE trial documented 50-60 percent reduction in new vertebral fractures with raloxifene therapy compared to placebo in postmenopausal osteoporosis patients.
🎀 Understanding Breast Cancer Prevention
Estrogen and Breast Cancer
Estrogen is a major driver of hormone receptor positive breast cancer - the most common breast cancer subtype affecting approximately 70 percent of breast cancer cases. Estrogen binds estrogen receptors in breast tissue stimulating cellular proliferation which drives both normal breast development and hormone receptor positive breast cancer growth. Postmenopausal women with elevated breast cancer risk (family history, Gail Model risk assessment above threshold, atypical hyperplasia, lobular carcinoma in situ) benefit from anti-estrogen preventive therapy.
Raloxifene Breast Cancer Prevention Mechanism
Raloxifene acts as estrogen antagonist at breast tissue - binding estrogen receptors and preventing estrogen from stimulating breast cell proliferation. This blocks the estrogen-driven cellular growth that drives hormone receptor positive breast cancer development. The STAR trial (Study of Tamoxifen and Raloxifene) 2006 demonstrated raloxifene equivalent to tamoxifen for invasive breast cancer prevention with 76 percent reduction versus placebo in high-risk postmenopausal women, and superior safety profile with fewer venous thromboembolic events and no endometrial cancer risk.
🎯 FDA Approved Indications
- Postmenopausal Osteoporosis Prevention
- Prevention of postmenopausal osteoporosis in women at risk. Initiated when postmenopausal bone loss begins and continued for years of preventive protection. Standard dosing: 60 mg daily continuous therapy.
- Postmenopausal Osteoporosis Treatment
- Treatment of established postmenopausal osteoporosis defined by DEXA scan T-score at or below negative 2.5 or presence of fragility fracture. Reduces vertebral fracture risk 50-60 percent per MORE trial. Standard dosing: 60 mg daily continuous therapy.
- Invasive Breast Cancer Risk Reduction
- Reduction of invasive breast cancer risk in high-risk postmenopausal women per STAR trial evidence. High-risk definition includes elevated Gail Model risk score, family history, atypical hyperplasia, or lobular carcinoma in situ. Standard dosing: 60 mg daily for 5 years of preventive therapy.
- Combined Osteoporosis and Breast Cancer Prevention
- Ideal candidates are postmenopausal women with both osteoporosis risk and elevated invasive breast cancer risk. Single medication provides simultaneous protection for both indications. Standard dosing: 60 mg daily continuous therapy for years of dual protection.
👤 Ideal Patient Selection
Evista most appropriate for:
- Postmenopausal women with established osteoporosis (T-score at or below negative 2.5)
- Postmenopausal women at risk for osteoporosis with osteopenia and additional risk factors
- Postmenopausal women with elevated invasive breast cancer risk (Gail Model, family history)
- Postmenopausal women with both osteoporosis and breast cancer risk (ideal dual indication)
- Women unable or unwilling to use estrogen HRT for osteoporosis prevention
- Women with atypical hyperplasia or lobular carcinoma in situ on breast biopsy
- Women without venous thromboembolism history
- Women without prolonged immobilization risk
- Women without significant cardiovascular disease
- Women without severe hot flash symptoms
- Women who have completed menopause (no premenopausal use)
- Women without hepatic impairment
- Women accepting long-term continuous therapy
🚫 Contraindications
Absolute Contraindications
- Active or history of venous thromboembolic events (DVT, PE, retinal vein thrombosis)
- Pregnancy or possibility of pregnancy - Pregnancy Category X
- Premenopausal women - not indicated for use
- Breastfeeding women - potential effects on nursing infant
- Hypersensitivity to raloxifene or tablet excipients
- Severe hepatic impairment - insufficient safety data
- Uncontrolled hypertension
- Prolonged immobilization - increases VTE risk further
Critical VTE Warning
CRITICAL: Venous Thromboembolism Warning
Raloxifene increases venous thromboembolism risk approximately 3-fold compared to placebo. Highest risk occurs during the first 4 months of therapy. VTE risk includes deep vein thrombosis (DVT), pulmonary embolism (PE), and retinal vein thrombosis.
VTE Risk Management:
- Discontinue at least 72 hours before prolonged immobilization (surgery, extended travel)
- Do not restart until fully mobilized
- Increased risk in women over age 70
- Increased risk with smoking, obesity, cardiovascular disease
- Report leg pain swelling redness or shortness of breath immediately
- Higher risk than tamoxifen and comparable to estrogen therapy
Stroke Death Risk in Cardiovascular Disease
RUTH Trial Cardiovascular Warning:
The RUTH trial (Raloxifene Use for The Heart) 2006 demonstrated no cardiovascular event reduction with raloxifene therapy. However, women with documented coronary heart disease or elevated coronary risk showed increased stroke death risk with raloxifene. Consider cardiovascular risk carefully before prescribing to women with existing cardiovascular disease.
Precautions
Use with caution in:
- Age over 70: Increased VTE and cardiovascular risk
- Cardiovascular disease history: RUTH trial safety concerns
- Smoking: Increases VTE and cardiovascular risks substantially
- Obesity: Increased VTE risk
- Hepatic impairment: Mild-moderate - use with caution
- Severe hot flash history: May exacerbate vasomotor symptoms
- Hypertriglyceridemia: Monitor lipid response
- Vaginal bleeding: Requires diagnostic evaluation before initiation
💉 Dosing and Administration
Standard Dosing
Standard raloxifene dosing:
- Standard dose: 60 mg once daily continuous
- Timing: Any time of day - may take with or without food
- Duration for osteoporosis: Long-term continuous therapy (years)
- Duration for breast cancer prevention: 5 years standard duration
- No dose adjustment for age, renal impairment, or moderate hepatic function
- No dose titration needed - start at full 60 mg dose
Administration Guidelines
- Take one 60 mg tablet daily at approximately the same time each day
- May be taken with or without food
- Take with water - swallow tablet whole
- Do not double dose if missed - resume next scheduled dose
- Continue therapy for prescribed duration - do not discontinue abruptly
- Adequate calcium and vitamin D intake essential for osteoporosis efficacy
- Discontinue at least 72 hours before prolonged immobilization or surgery
- Do not restart until fully mobilized after surgery or immobilization
- Report VTE symptoms immediately (leg pain swelling shortness of breath)
- Regular monitoring appointments with prescriber
- DEXA scan every 1-2 years to monitor bone density response
- Regular breast cancer screening (mammography) mandatory
📊 Key Clinical Trials
MORE Trial (Multiple Outcomes of Raloxifene Evaluation)
MORE trial results (1999):
- 7,705 postmenopausal osteoporosis patients enrolled
- 50-60 percent vertebral fracture reduction vs placebo over 3 years
- No significant hip fracture reduction demonstrated
- Substantial bone density improvement at spine and hip
- 76 percent invasive breast cancer risk reduction as secondary endpoint (led to STAR trial)
- 3-fold VTE risk increase vs placebo
- No endometrial cancer risk increase - key safety finding
STAR Trial (Study of Tamoxifen and Raloxifene)
STAR trial results (2006):
- 19,747 high-risk postmenopausal women enrolled
- Equivalent invasive breast cancer prevention raloxifene vs tamoxifen
- Fewer VTE events with raloxifene than tamoxifen
- No endometrial cancer excess with raloxifene (tamoxifen showed excess)
- Fewer cataracts with raloxifene than tamoxifen
- Led to 2007 FDA approval for raloxifene invasive breast cancer risk reduction
- Established raloxifene as preferred SERM for postmenopausal breast cancer prevention
RUTH Trial (Raloxifene Use for The Heart)
RUTH trial results (2006):
- 10,101 postmenopausal women with cardiovascular disease or high risk
- No cardiovascular event reduction with raloxifene therapy
- Confirmed invasive breast cancer risk reduction in general postmenopausal population
- Increased stroke death risk in women with existing cardiovascular disease
- Increased VTE risk confirmed in cardiovascular population
- Established caution for raloxifene use in cardiovascular disease patients
⚠️ Side Effects
Common Side Effects
- Hot flashes: Common - may worsen existing hot flashes or trigger new ones (approximately 25 percent)
- Leg cramps: Common - approximately 12 percent
- Peripheral edema: Common - typically mild
- Flu-like symptoms: Occasional
- Sinusitis: Occasional
- Sweating: Occasional
- Insomnia: Uncommon
- Depression or mood changes: Uncommon
- Weight gain: Uncommon
- Breast pain: Uncommon - typically mild
- Vaginal bleeding: Uncommon - requires evaluation if present
- Nausea: Uncommon
- Rash: Uncommon
Serious Adverse Events
Seek immediate medical attention for:
- Signs of deep vein thrombosis: Leg pain swelling redness warmth
- Signs of pulmonary embolism: Chest pain shortness of breath rapid breathing
- Signs of retinal vein thrombosis: Sudden vision changes vision loss
- Signs of stroke: Sudden numbness weakness speech difficulty confusion
- Severe leg cramps or persistent pain
- Chest pain
- Sudden shortness of breath
- Signs of allergic reaction
- Unusual vaginal bleeding
- Signs of liver dysfunction: Jaundice dark urine severe abdominal pain
- Breast changes or breast lump
🔄 Drug Interactions
| Drug/Substance | Interaction |
|---|---|
| Cholestyramine | Reduces raloxifene absorption by 60 percent - avoid combination |
| Warfarin | Modest decrease in prothrombin time - monitor INR |
| Estrogens (systemic) | Not concurrently prescribed - no combination therapy |
| Highly protein-bound drugs | Minimal displacement - clinically insignificant typically |
| Ampicillin | May reduce raloxifene absorption |
| Antacids (aluminum/magnesium) | No significant interaction |
| Digoxin | No significant interaction |
| Corticosteroids | Additive bone loss concerns - monitor bone density |
| Calcium supplements | Recommended concurrent use for osteoporosis therapy |
| Vitamin D supplements | Recommended concurrent use for osteoporosis therapy |
| Smoking | Substantially increases VTE and cardiovascular risks |
🛡️ Special Populations
- Postmenopausal Women
- Primary target population for all Evista indications. Comprehensive baseline assessment including DEXA scan for osteoporosis, breast cancer risk assessment, cardiovascular risk evaluation, and VTE risk assessment.
- Premenopausal Women
- Contraindicated. Evista not indicated for premenopausal use. Pregnancy Category X - potential fetal harm. Effective contraception mandatory if reproductive potential remains.
- Elderly Women (Over 70)
- Increased VTE and cardiovascular risk. Comprehensive risk assessment. Individualized decision balancing bone protection and breast cancer prevention against thromboembolic risk.
- Women with Osteoporosis
- Standard indication. DEXA scan monitoring every 1-2 years. Adequate calcium (1200 mg daily) and vitamin D (800-1000 IU daily) intake essential for efficacy.
- High Breast Cancer Risk Women
- Standard indication per STAR trial evidence. Gail Model risk assessment above threshold, family history, atypical hyperplasia, or LCIS. 5-year standard duration.
- Cardiovascular Disease Patients
- RUTH trial safety concerns. Increased stroke death risk. Alternative therapies often preferred. Individualized risk-benefit assessment essential.
- VTE History Patients
- Contraindicated. Active or history of DVT, PE, retinal vein thrombosis excludes raloxifene therapy. Alternative bone protection agents needed.
- Smokers
- Substantially increased VTE and cardiovascular risks. Smoking cessation strongly recommended before starting therapy. Alternative therapies may be preferred.
- Hepatic Impairment
- Severe hepatic impairment contraindicated. Mild-moderate impairment use with caution. Monitor liver function periodically.
- Renal Impairment
- Standard dosing generally appropriate. No specific dose adjustments needed. Monitor renal function periodically.
- Prolonged Immobilization
- Discontinue at least 72 hours before planned prolonged immobilization (surgery, extended travel, hospitalization). Do not restart until fully mobilized.
📦 Storage and Handling
- Store at room temperature 20-25°C (68-77°F)
- Protect from light and moisture
- Keep tablets in original packaging
- Keep out of reach of children and pets
- Do not use past expiration date
- Do not share medication with others
- Return unused medication to pharmacy for proper disposal
- Store in dry area - avoid humid bathrooms
👨⚕️ When to Contact Your Doctor
- Signs of DVT: leg pain swelling redness warmth
- Signs of pulmonary embolism: chest pain shortness of breath rapid breathing
- Signs of retinal vein thrombosis: sudden vision changes vision loss
- Signs of stroke: sudden numbness weakness speech difficulty
- Chest pain or severe leg cramps
- Sudden shortness of breath
- Breast lump or breast changes
- Unusual or persistent vaginal bleeding
- Signs of liver dysfunction: jaundice dark urine
- Severe hot flashes affecting quality of life
- Signs of severe allergic reaction
- Planned surgery or prolonged immobilization
- Extended travel with prolonged sitting
- Suspected pregnancy
- Time for scheduled monitoring appointments
- Time for DEXA scan (every 1-2 years)
- Time for annual breast cancer screening (mammography)
- Starting new medications potentially interacting
- Consideration of therapy duration reassessment
🌟 Key Takeaways
Essential points about Evista therapy:
- Evista is Cipla generic raloxifene 60 mg tablets - original Eli Lilly brand identity
- Original brand FDA-approved 1997 (osteoporosis) with additional 2007 approval (breast cancer prevention)
- Over 25 years continuous clinical use worldwide
- Second-generation Selective Estrogen Receptor Modulator (SERM)
- Benzothiophene chemistry - structurally distinct from tamoxifen
- Tissue-selective mechanism: bone agonist, breast antagonist, endometrial antagonist
- DUAL FDA-approved indications: postmenopausal osteoporosis and invasive breast cancer risk reduction
- Standard dosing 60 mg once daily continuous - simple therapy
- May be taken with or without food any time of day
- MORE trial: 50-60 percent vertebral fracture reduction in osteoporosis
- STAR trial: 76 percent invasive breast cancer risk reduction in high-risk postmenopausal women
- Equivalent breast cancer prevention to tamoxifen with fewer VTE events
- No endometrial cancer risk (major safety advantage over tamoxifen)
- No vasomotor symptom relief (may worsen hot flashes)
- CRITICAL: 3-fold VTE risk increase - deep vein thrombosis pulmonary embolism retinal vein thrombosis
- Contraindicated in VTE history, pregnancy, premenopausal use, hepatic impairment
- Discontinue 72 hours before prolonged immobilization or surgery
- Increased stroke death risk in cardiovascular disease patients (RUTH trial)
- Adequate calcium (1200 mg) and vitamin D (800-1000 IU) intake essential for osteoporosis efficacy
- DEXA scan monitoring every 1-2 years
- Regular breast cancer screening (mammography) mandatory during therapy
Important Medical Disclaimer: This medication guide provides general information about Evista (Cipla generic raloxifene 60 mg tablets) and does not constitute individualized medical advice. Every patient situation is unique and requires evaluation by a gynecologist endocrinologist or qualified healthcare provider before starting Selective Estrogen Receptor Modulator therapy. Evista requires comprehensive baseline workup including DEXA scan for bone density assessment, breast cancer risk assessment (Gail Model, family history evaluation), pelvic examination, mammography for baseline breast screening, cardiovascular risk assessment, VTE risk evaluation, and hepatic function testing before initiation. CRITICAL SAFETY: Evista carries substantial venous thromboembolism warnings including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. Risk is approximately 3-fold higher than placebo and highest during first 4 months of therapy. Discontinue at least 72 hours before prolonged immobilization, surgery, or extended travel. Do not restart until fully mobilized. Contraindicated in active or history of venous thromboembolism, pregnancy (Category X), premenopausal women, breastfeeding, hepatic impairment, and hypersensitivity. RUTH trial demonstrated no cardiovascular event reduction and increased stroke death risk in women with existing cardiovascular disease - individualized risk-benefit assessment essential. Not for vasomotor symptom relief - may worsen hot flashes. Adequate calcium (1200 mg daily) and vitamin D (800-1000 IU daily) intake essential for osteoporosis efficacy. Regular monitoring includes DEXA scan every 1-2 years and mandatory annual breast cancer screening (mammography). Report symptoms of DVT (leg pain swelling), PE (chest pain shortness of breath), retinal vein thrombosis (sudden vision changes), stroke, breast changes, or unusual bleeding immediately. Smoking substantially increases VTE and cardiovascular risks - smoking cessation strongly recommended. Long-term therapy requires periodic reassessment weighing continued bone protection and breast cancer prevention benefits against cumulative risks. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance from your gynecologist endocrinologist or oncologist.
More Women's Health Medications
